Foresee Pharmaceuticals reports positive Phase 1 trial results for Linvemastat
Foresee Pharmaceuticals (TPEx: 6576) has reported successful preliminary results from its Phase 1 clinical trial of linvemastat (FP-020), an innovative and selective matrix metalloproteinase-12 (MMP-12) ... Read More
Foresee Pharmaceuticals begins FP-025 phase 2/3 trial in Covid-19 associated ARDS
Foresee Pharmaceuticals has started patient dosing in a phase 2/3 trial of FP-025 in adults having severe to critical Covid-19 with associated acute respiratory distress ... Read More